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Alternatively Activated Macrophages Play an Important Role in
Vascular Remodeling and Hemorrhaging in Patients with Brain
Arteriovenous Malformation
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Background: Angiogenic and immunoactive lesions in brain arteriovenous mal-
formation (BAVM) contribute to hemorrhagic events and the growth of BAVMs.
However, the detailed mechanism is unclear. Our objective is to clarify the rela-
tionship between hemorrhagic events of BAVM and alternatively activated
macrophages in the perinidal dilated capillary network (PDCN). Methods: We ex-
amined microsurgical specimens of BVMs (n = 29) and focused on the PDCN area.
Ten autopsied brains without intracranial disease were the controls. We per-
formed immunostaining of the inflammatory and endothelial cell markers, macrophage
markers (CD163 and CD68), and vascular endothelial growth factor A (VEGF-A).
We evaluated each cell’s density and the vessel density in the PDCN and ana-
lyzed the relationship to hemorrhagic events of BAVM. Results: The PDCN was
involved in all the resected arteriovenous malformations, and these vessels showed
a high rate of CD105 expression (72.0 ± 10.64%), indicating newly proliferating vessels.
Alternatively activated macrophages were found, with a high rate (85.6%) for all
macrophages (controls, 56.6%). In the hemorrhagic cases, the cell density was sig-
nificantly higher than that in the nonhemorrhagic cases and controls (hemorrhagic
group, 290 ± 44 cells/mm2; nonhemorrhagic group, 180 ± 59 cells/mm2; and control,
19 ± 8 cells/mm2). The cell density of alternatively activated macrophages showed
a positive correlation with the vessel density of the PDCN. Double immunostaining
showed that VEGF-A was secreted by alternatively activated macrophages. Con-
clusion: Our data suggest that alternatively activated macrophages may have some
relationships with angiogenesis of PDCN and hemorrhagic event of BAVM. Key
Words: Arteriovenous malformation—alternatively activated macrophage—perinidal
dilated capillary network—vascular remodeling—VEGF.
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Introduction
Brain arteriovenous malformation (BAVM) is a major
cause of hemorrhagic stroke in young patients. There-
fore, a key therapeutic strategy is the prevention of bleeding
and rebleeding. Multimodal therapies such as gamma knife,
endovascular embolization, surgical resection, and a com-
bination of these therapies are available.1 However, some
patients are not able to receive these treatments because
of untreatable lesions (e.g., a large size, eloquent area,
and deep drainer).2 In addition, even if BAVM appears
to be resolved, it sometimes recurs or rebleeds.3 Thus, it
is essential to clarify the pathogenesis and mechanism
of rupture in BAVM. Although a satisfactory sporadic
BAVM animal model does not exist, some recent reports
have described the pathogenesis of BAVM.
Recently, some investigators demonstrated that areas
containing dilated vessels existed in the perinidal space
(i.e., the perinidal dilated capillary network [PDCN]). In
a 3-dimensional anatomical study, Sato et al4 reported that
the PDCN is connected to the nidus, feeding arteries, and
draining veins via the arterioles and venules, as well as
to the normal capillaries, arterioles, and venules. Tu et al5
reported that the perinidal capillaries demonstrated an
abnormal ultrastructure of the blood–brain barrier with
no basement membranes or astrocytic foot processes. These
vessels are related to intraoperative and postoperative
hemorrhages.4,5 Some studies have reported that angio-
genic or cell proliferating factors and signals (vascular
endothelial growth factor [VEGF], platelet-derived growth
factor, notch, and nuclear factor-κB) were detected in
human BAVM samples.6-9 Furthermore, endothelial cells
of arteriovenous malformation (AVM) showed more fre-
quent apoptosis and proliferation than normal controls
in a culture study.10 Therefore, BAVM and perinidal dilated
capillaries are not considered static congenital lesions;
instead, they are dynamically growing (or changing) lesions
of their own.11
Chen et al12 described that an aberrant immune re-
sponse was an important factor of vascular remodeling
in the BAVM microenvironment. They also found that
macrophages and neutrophils infiltrate more frequently
than lymphocytes in BAVM tissue. Recent studies showed
that the macrophages act as cellular chaperones for vas-
cular anastomosis and remodeling of the extracellular
matrix.13,14 However, it is unclear whether these mac-
rophages are associated with vascular remodeling in BAVM
tissue.
Macrophage activation is clearly divided into 2 path-
ways: classical activation (changing to M1 phenotype) and
alternative activation (changing to M2 phenotype).15-18 Clas-
sical activation is induced by bacterial products (e.g.,
lipopolysaccharides) and interferon-γ. In contrast, alter-
native activation is induced by Th2-type cytokines such
as interleukin (IL)-4, IL-10, IL-13, vitamin D3, the mac-
rophage colony stimulation factor, or a glucocorticoid.15-18
Alternatively activated macrophages/microglia are asso-
ciated with a high degree of vascularization, which
influences wound repair.19,20 In some malignant tumors,
alternatively activated macrophages are tumor-associated
macrophages (TAMs), which are associated with poor prog-
nosis in breast, colon, prostate, glioma, and cervical cancers.
TAMs promote invasion, growth, angiogenesis, and me-
tastasis of malignant tumors.21-25
Our study focused on alternatively activated mac-
rophages (i.e., M2 macrophage or TAMs) in BAVM. We
used the antibody (Ab) for CD163, a member of the scav-
enger receptor cysteine-rich superfamily restricted to
monocyte/macrophage lineage, which is a useful marker
for anti-inflammatory or alternatively activated
macrophages.26 We aimed to investigate the origin of the
dilated capillary network, analyze the macrophage phe-
notype and function, and clarify the relationship between
macrophages and dilated capillary vessel formation in sur-
gically resected BAVM samples.
Methods
Patients
We surgically removed 28 BAVMs at the Kurume Uni-
versity Hospital between 1996 and 2010. The clinical data
are summarized in Table 1; 19 patients were hemorrhag-
ic cases and 9 were nonhemorrhagic cases. Ten autopsied
brains without intracranial disease were the controls. The
patients’ mean age was 43.1 ± 12.4 years, and 11 were
female. In the nonhemorrhagic cases, 3 patients had AVM
at seizure onset, while the other AVMs were discovered
incidentally. The nidus size ranged from 8 to 55 mm (mean,
25.3 mm). Four patients’ AVMs were Spetzler–Martin grade
I, 15 were grade II, and 10 were grade III. Of all 19 hem-
orrhagic cases, 15 (78.9%) cases underwent acute phase
removal surgery (within 48 hours after the hemorrhagic
event).
Abs
The following Abs were used in the present study:
anti-CD3 Ab as a T-lymphocyte marker (1:100; Novocastra,
Leica Biosystems, Newcastle, UK), anti-CD20 Ab
as a B-lymphocyte marker (1:1000; Dako Corporation,
Carpinteria, CA), antimyeloperoxidase Ab as a neutro-
phil marker (1:4000, Dako Corporation), rabbit and
mouse anti-CD68 Abs as a macrophage marker
(1:200; Dako, Grostrup, Denmark), anti-CD163 Ab (1:200,
Novocastra) for recognizing macrophage-restricted mem-
brane protein, anti-CD34 as a vascular endothelial cell
marker (1:200; Immunotech, Marseille, France), antihu-
man CD105 Ab (antiendoglin, 1:200; Dako Corporation),
and anti-VEGF (A20, sc-120) and antivascular endothe-
lial growth factor A (VEGF-A) Abs (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA). In the present study,
alternatively activated macrophages were recognized as
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the cells that showed positive immunostaining for both
CD68 and CD163.26,27
Immunohistochemistry
All the specimens were fixed in 10% formalin for
12 hours, were embedded in paraffin (formalin-fixed
paraffin-embedded), and were stored at room tempera-
ture. All the formalin-fixed paraffin-embedded speci-
mens were cut into 5–μm-thick tissue sections. For
single-label immunohistochemistry, the sections were
deparaffinized and rehydrated with graded ethanol.
Antigen unmasking was performed using ethylenedi-
amine tetraacetic acid for 10 minutes at 95°C. After
removing the blocking solution, 100 μL of primary diluted
Ab was added to each section and incubated for 30 minutes
at room temperature. After the reactions of each antigen-
specific Ab was obtained, the samples were incubated with
horseradish peroxidase-labeled goat antimouse (or rabbit)
Ab (Nichirei, Tokyo, Japan). After rinsing with .01 mol/L
of phosphate-buffered saline 3 times for 5 minutes, the
reaction was visualized by means of the diaminobenzidine
substrate system (Nichirei).
Next, for double immunostaining, antigen unmask-
ing was performed using ethylenediamine tetraacetic acid
for 5 minutes at 95°C. Diluted primary Abs were added
to each section and were incubated for 30 minutes at room
temperature. After rinsing with phosphate-buffered saline
(3 times for 5 minutes), the second reaction was visual-
ized by using the Vector VIP substrate kit for peroxidase
(SK-4600; Vector Laboratories, Burlingame, CA). Some
frozen samples were selected for double fluorescent stain-
ing, and after being incubated at 4°C for 24 hours with
the primary Abs, the sections were incubated with Alexa
Flour 488-conjugated goat antirabbit IgG or Alexa Flour
594-conjugated goat antimouth (Molecular Probes, Eugene,
OR).
PDCN
The PDCNs were defined as follows: more than 50 μm
in diameter and located in the perinidal brain paren-
chyma within 1-10 mm from the AVM border (Fig 1, A,B).
These vessels were counted in the perinidal area of all
the specimens, and the vessel density (count/cm2) was
calculated.
Assessing the Cell Counts
All the tissue sections were measured using the Na-
tional Institutes of Health ImageJ program (National
Institutes of Health, New York City, NY) in square mil-
limeter. Infiltrating cells were defined as the presence of
a vascular wall, perivascular space, and brain paren-
chyma. Cell counts were performed in 5 areas that were
randomly selected far from the hemorrhage site and were
calculated using average counts per square millimeter (cell
number/mm2). Cell counts of the normal controls were
counted in the same manner. In the CD68 and CD163
double immunostained specimens, the CD68-positive cells
and CD68-/CD163-double positive cells were counted on
a field with ×200 magnification.
Statistical Analysis
The counts are presented as the mean ± standard de-
viation, and they were analyzed using Student t-test for
each group. The statistical analysis was performed using
Table 1. Summary of patients with brain arteriovenous malformations
Characteristics Hemorrhage group Nonhemorrhage group
No. of cases n = 19 n = 9
Age
Mean ± SD 49.42 ± 20.91 43.89 ± 12.42
Range 8-64 8-40
Sex (male) 12 (63.2%) 5 (55.6%)
BAVM size (mm)
Mean ± SD 23.32 ± 11.11 21.22 ± 10.06
Range 5-50 8-40
Spetzler–Martin grade
1 1 1
2 11 6
3 7 2
4 0 0
5 0 0
AVM localization
Superficial 11 8
Deep 8 1
Abbreviations: AVM, arteriovenous malformation; BAVM, brain arteriovenous malformation; no., number; SD, standard deviation.
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JMP 9 (SAS Institute Inc., Cary, NC). P values less than
.05 were considered significant.
Results
Perinidal Dilated Capillary Vessels Surrounding
the BAVM
All the cases had the PDCN area in the perinidal brain
parenchyma (Fig 1, A,B), and the mean vessel density
was 99 ± 74 vessels/cm2 (n = 28). There were no signif-
icant differences in the nidal size or hemorrhagic events.
CD105-positive endothelial cells were observed in the
perinidal dilated capillary vessels (mean, 72.0 ± 10.64%)
(Fig 1, C), whereas only 1.4 ± .23% (mean) of CD105-
positive vessels were found in normal brain parenchyma.
These positive rates of CD105 immunostaining showed
no significant difference between the hemorrhagic and
nonhemorrhagic AVM groups. CD163-positive cells were
frequently found in these areas (Fig 1, D, white arrow).
The mean positive rate of CD163 (the percentage of al-
ternative activation) in all the macrophages of all the AVMs
was 85.14 ± 3.53%, which is significantly higher than that
of normal brain macrophages (56.59 ± 28.74%, P < .01).
Quantitative Analysis of Inflammatory Cell Infiltration
First, we analyzed the inflammatory cells of the T cell,
B cell, neutrophil, and general macrophages (Fig 2). All
the types of inflammatory cells were observed in the peri-
vascular space and brain parenchyma.
The cell density of CD3-positive cells (a T-lymphocyte
marker) in the hemorrhagic and nonhemorrhagic cases
was significantly higher than that of the controls (hem-
orrhagic cases: 96.7 ± 16.3 cells/mm2, P = .0005;
nonhemorrhagic cases: 88.4 ± 15.6 cells/mm2, P = .01; con-
trols: 6.2 ± 1.4 cells/mm2). However, there were no
significant differences between the hemorrhagic and
nonhemorrhagic cases (P = .73; Fig 2, A).
The cell density of the CD20-positive cells (a B-lymphocyte
marker) of hemorrhagic cases was significantly higher than
that of the nonhemorrhagic cases (P = .01) and that of the
controls (P < .0001) (hemorrhagic cases: 60.1 ± 34.6 cells/
mm2; nonhemorrhagic cases: 31.0 ± 21.3 cells/mm2; controls:
4.4 ± 3.7 cells/mm2; Fig 2, B).
The cell density of myeloperoxidase-positive cells (a
neutrophil marker) of the hemorrhagic and nonhemorrhagic
cases was significantly higher than that of the controls
(hemorrhagic cases: 286.1 ± 199.4 cells/mm2, P ≤ .0001;
nonhemorrhagic cases: 407.0 ± 275.9 cells/mm2, P = .011;
controls: 9.0 ± 3.2 cells/mm2). There was no significant dif-
ference between the hemorrhagic and nonhemorrhagic cases
(P = .14; Fig 2, C).
The CD68-positive cells (a macrophage marker) were
generally observed in the vascular wall, perivascular space,
and brain parenchyma. The cell density of the CD68-
positive cells in the hemorrhagic cases was higher
(342.3 ± 167.9 cells/mm2) than that of the nonhemorrhagic
cases (207.4 ± 94.9 cells/mm2). The cell density of the CD68-
positive cells of the controls was the lowest
(19.8 ± 13.3 cells/mm2) among the 3 groups, and there was
a statistically significant difference among all the groups
(P < .01; Fig 2, D).
Alternatively Activated Macrophages in the
BAVM Tissue
The CD68-positive cells in BAVM showed a high
coexpression of the CD163 antigen (Fig 3), and the cell
Figure 1. H&E staining (low power magnifi-
cation, A; high power magnification, B) showing
perinidal dilated capillary vessels around the AVM.
Dilated vessels are defined as more than 50 μm
of their luminal size. The brain AVM nidus ex-
pressed CD105 in the endothelial cells of AVM
(C) and CD163-positive macrophage (D, violet
portion) exists near the perinidal capillary vessels
(D, brown portion). Abbreviations: AVM, arte-
riovenous malformation; H&E, hematoxylin and
eosin. (Color version of figure is available online.)
ACTIVATED MACROPHAGES IN ARTERIOVENOUS MALFORMATION 603
density of CD163- and CD68-double positive cells was
significantly higher than that of the controls (AVM:
283 ± 123 cells/mm2 versus controls: 19 ± 11 cells/mm2;
P < .0001). In hemorrhagic cases, the cell density of al-
ternatively activated macrophages (CD163- and CD68-
double positive cells) was significantly higher than that
of the nonhemorrhagic and controls (hemorrhagic group:
283 ± 123 cells/mm2, nonhemorrhagic group: 183 ± 81 cells/
mm2, and controls: 19 ± 11 cells/mm2; Fig 4, A).
Correlation between the Alternatively Activated
Macrophage and Dilated Capillary Vessel Density
When analyzing the relationship between the vessel
density and the cell density of the CD163- and CD68-
double positive cells (alternatively activated macrophages),
a significant positive correlation was found in the hem-
orrhagic AVM group; however, no correlation was found
in the nonhemorrhagic AVM group (Fig 4, B,C). In VEGF-A
and CD163 double staining, the CD163-positive cells
contained VEGF-A and were located in the vascular sprout-
ing and fusion site (Fig 5, A). CD163-positive cell
infiltrations were frequently found near small vessels in
the hemorrhagic and nonhemorrhagic cases, and these
cells contained VEGF (Fig 5, B,C).
Discussion
In the present study, all the BAVM specimens had areas
containing the PDCN,4,5 which is clearly distinguished from
the BAVM nidus itself. We performed immunohistochem-
istry of CD105 (endoglin) and obtained a high CD105-
positive ratio (72.0 ± 10.64%) in the vascular endothelial
cells of these areas, while there were rare CD105-
positive cells in the normal brain. CD105 is a
transmembrane auxiliary receptor for the transforming
growth factor-β (TGF-β), which is predominantly ex-
pressed in proliferating endothelial cells.28 Thus, these
findings suggest that most of these vessels were newly
proliferated. Many investigators have suggested that BAVM
Figure 2. Quantity analysis of the inflammatory cell infiltration. The CD3-positive T cells (A), CD20-positive B cells (B), myeloperoxidase-positive neu-
trophils (C), and CD68-positive macrophage (D) are analyzed among the H, non-H, and Ctl groups. The vertical bars indicate the number of cells per
square millimeter. Abbreviations: AVM, arteriovenous malformation; Ctl, control; H, hemorrhagic AVM; non-H, nonhemorrhagic AVM.
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Figure 3. CD68 (A) and CD163 (B)
immnofluorescent staining and nuclear staining
(C). The dotted gray lines show the endothelium
layer of the large vessels. CD68- and CD163-
double positive macrophage infiltration is observed
in the perivascular space (D, merged images of
A and B). DAPI, 4′,6-diamidino-2-phenylindole.
Figure 4. Alternatively activated macrophage (CD163- and CD68-double positive cells) exist more frequently in the hemorrhagic AVM (H group) compared
to the other groups (non-H, nonhemorrhagic group; C, control group) in the AVM perinidal area (A). The relationship between the vessel density in the
perinidal area and the alternatively activated macrophages in hemorrhagic AVM (B) and nonhemorrhagic AVM (c). Abbreviation: AVM, arteriovenous malformation.
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has angiogenic activity of its own, and these capillaries
may originate from AVM. Alternatively, other angio-
genic factors (cells) may act to proliferate normal capillary
vessels, which are connected to the BAVM nidus and other
dilated capillary vessels.
At first, we performed a quantitative analysis of the
inflammatory cells in hemorrhagic and nonhemorrhagic
AVMs, and in normal controls. In the AVM samples, the
number of all the inflammatory cells was significantly
higher than that in the controls; particularly, the neutro-
phils and macrophages were obvious in contrast to the
T and B lymphocytes. Our data correspond to a previ-
ous study by Chen et al,12 who focused on the immune
response in BAVM. Chen et al showed that infiltrating
neutrophils and macrophages are observed in
nonhemorrhagic BAVMs, and neutrophil-derived MMP-9
is significantly higher in hemorrhagic cases. Similarly, our
data showed the significant increase of neutrophil infil-
tration in both hemorrhagic and nonhemorrhagic AVMs,
but there was no statistically significant difference between
these 2 groups. Alternatively, our data showed that only
macrophage infiltration was correlated with a hemor-
rhagic event. Therefore, we analyzed the macrophage
phenotype and function.
CD163- and CD68-double positive cells (alternatively
activates macrophage) were observed in the vascular wall,
perivascular space, and brain parenchyma. Previous studies
reported that CD163-positive macrophages infiltrate into
some malignancies (e.g., T-cell lymphoma and glioma).27,29
Furthermore, it was reported that the parenchymal CD163-
positive macrophages/microglia have the capacity for
antigen ingestion and presentation, which may contrib-
ute to the resolution of inflammation in multiple
sclerosis.30,31 In our study, about 85% of the mac-
rophages coexpressed the CD163 antigen. However, we
cannot explain the reason for this high rate. Mahmoud
et al32 reported that TGF-β can polarize macrophage M1
to the M2 phenotype. Furthermore, it was reported that
TGF-β signaling plays a key role in hereditary hemor-
rhagic telangiectasia and sporadic AVM.33 TGF-β may also
contribute to the alternative activation of macrophages
in the BAVM microenvironment.
Our data showed that alternative activated mac-
rophages were positively associated with the number of
dilated vessels in hemorrhagic AVM. Tu et al5 reported
that dilated capillary vessels lack the BBB, so they may
be associated with intraoperative and postoperative hem-
orrhage, growth, and recurrence of surgically treated BAVM.
Our findings suggest that alternatively activated mac-
rophages have an angiogenic potential and play a key
role in dilated capillary vessel formation. A previous study
proved that alternatively activated macrophages had a
higher angiogenic activity in poor prognostic follicular
lymphoma, and other studies demonstrated an associa-
tion between the vascular sprouting and numbers of
infiltrating CD163-positive macrophages.34 According to
our double immunostaining of VEGF-A and CD163,
double-positive macrophages were localized in the nidal
vascular wall and perivascular space (outside of the CD34
positive layer); furthermore, they were localized in the
dilated vessels sprouting and fusion sites. Some studies
have suggested that BAVM endothelium has a potential
Figure 5. Double immunostaining showing vas-
cular endothelial growth factor secretion (brown)
and CD163-positive macrophages (violet). (A) High-
power magnification; (B) hemorrhagic AVM;
(C) nonhemorrhagic AVM. Abbreviation: AVM,
arteriovenous malformation. (Color version of figure
is available online.)
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for angiogenesis.8-10 Thus, alternatively activated mac-
rophages may also contribute to angiogenesis in BAVM
by secreting VEGF.
The infiltrating cell number of alternatively activated
macrophages in hemorrhagic AVM was significantly higher
than that of nonhemorrhagic AVM and the normal con-
trols. In posthemorrhage conditions, various inflammatory
cells, which secrete proinflammatory cytokines and clas-
sically activated macrophages, secrete TNF-α, IL-1, and
IL10 among other factors. In contrast, alternatively acti-
vated macrophages secrete anti-inflammatory cytokines
such as IL-10, IL-4, and TGF-β.35 Recently, it was re-
ported that alternatively activated macrophages are evoked
after a coronary intraplaque hemorrhage36 and that CD163-
positive cells may be recruited to hemorrhagic lesions to
reduce the heme toxicity.37 In addition, alternatively ac-
tivated macrophages are regarded as nearly the spectrum
of wound-healing macrophages.33 This evidence strongly
supports the response-to-injury model of the BAVM pa-
thology, which was proposed by Kim et al.38 Thus, there
is a possibility that alternatively activated macrophages
were recruited by the hemorrhagic events in our study.
In contrast, there is another possibility. Because sur-
gical resection was performed in the acute phase (within
48 hours after the hemorrhagic event) in most cases (15
of 19 hemorrhagic cases, 78.9%), infiltration of alterna-
tively activated macrophages may have occurred prior
to the major bleeding. Guo et al39 reported that silent
intralesional microhemorrhage (i.e., asymptomatic bleed-
ing in the nidal compartment) serves as a marker for the
increased risk of symptomatic intracranial hemorrhage.
The well-known function of CD163 (a hemoglobin scav-
enger receptor) is to bind to the hemoglobin–haptoglobin
complex, which may mediate extravasal hemolysis.28 Fur-
thermore, CD163-positive macrophages may cause
intralesional microhemorrhage through the formation of
perinidal dilated capillary vessels. These fragile vessels
lack the BBB, which may cause a hemorrhagic tenden-
cy, as previously mentioned (Fig 6). Thus, our data
suggested that alternatively activated macrophages may
Figure 6. Schematic drawings of the mecha-
nism of major bleeding of AVM. The PDCN exists
near the AVM nidus (A), and asymptomatic minor
hemorrhage (B) triggers the accumulation and in-
filtration of alternatively activated macrophages
to the PDCN (C). These alternatively activated
macrophages have anti-inflammatory factors and
VEGF, which increases the angiogenesis of PDCN.
This newly grown PDCN lacks the BBB, increas-
ing the risk of major bleeding after PDCN
proliferation. Even if there is no minor hemor-
rhage, accumulated and infiltrated alternatively
activated macrophages induce PDCN prolifera-
tion, which may cause major hemorrhage of AVM.
Abbreviations: AVM, arteriovenous malforma-
tion; BBB, blood–brain barrier; PDCN, perinidal
dilated capillary network; VEGF, vascular endo-
thelial growth factor.
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contribute to angiogenesis and hemorrhagic events, al-
though details are still unknown and further study is
necessary.
Conclusions
To clarify macrophage infiltration in BAVM tissue, we
investigated the macrophage phenotype and function using
the immunohistochemical method. Alternatively acti-
vated macrophages were infiltrated in surgically resected
BAVM tissue, especially in hemorrhagic cases, and in
PDCN. These findings suggest that alternatively acti-
vated macrophages may have a relationship with
angiogenesis of PDCN and hemorrhagic event of BAVM.
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